Beyond the glucose-lowering effect, SGLT2 inhibitors have been shown to reduce the risk of cardiovascular and renal diseases in patients with T2DM, heart failure (HF), or chronic kidney disease (CKD), and are currently recommended for preventing HF in diabetic patients with CKD and treating HF across the full spectrum of left ventricular ejection fraction (LVEF) [12,13,14,15,16]. This evidence concerns the gene SLC5A2 and heart failure.